针对非激酶和激酶的细胞活性,氨酸向的不可逆转共价抑制剂
Peng Chen1,2, Lu Wang3, Xuan Wang1,4
1Department of Chemistry, National University of Singapore, Singapore, 117543, Singapore.
Angewandte Chemie (International ed. in English)
|January 8, 2025
概括
研究人员开发了一种针对向共价抑制剂 (TCI) 的基于糖的新策略,该策略可以选择性地向Mcl-1和AURKA等蛋白质中的氨酸残留物. 这种方法为药物发现和针对困难蛋白质提供了新的工具.
科学领域:
- 药用化学 医学化学
- 化学生物学 化学生物学
- 药物发现 药物发现 药物发现
背景情况:
- 向共价抑制剂 (TCI) 在酶研究和药物发现中至关重要.
- 目前的TCI策略主要针对常见的氨基酸侧链.
- 将TCI能力扩展到其他氨基酸对于准具有挑战性的蛋白质至关重要.
研究的目的:
- 开发一种基于糖的新型策略,用于对氨酸有反应的TCI.
- 为了证明这种策略在向不同蛋白质方面具有普遍性.
- 探索这些TCI在药物耐药性的应用.
主要方法:
- 基于糖的小分子的设计和合成.
- 在体外和细胞测试中评估功效,选择性和反应性.
- 与标蛋白Mcl-1,AURKA和ALK激酶突变体的共价参与研究.
主要成果:
- 建立了一种基于glioxal的策略,以产生向氨酸残留物的强大和有选择性的TCI.
- 该策略通过创建Mcl-1和AURKA的抑制剂来验证,这些抑制剂针对特定的氨酸残留物 (分别是R263和R220).
- 化合物显示细胞活性,与内源性AURKA的共价参与,以及向耐药ALK激酶突变的潜力.
结论:
- 基于glioxal的TCI提供了一种多功能方法,用于向保存或溶剂暴露的氨酸残留物.
- 这一战略扩大了针对具有挑战性的目标开发共价抑制剂的工具箱.
- 这些发现对推进酶研究和克服药物耐药性的研究有意义.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.6K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.6K
Enzyme Inhibition
77.8K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
77.8K
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K


